04:21 PM EDT, 07/02/2024 (MT Newswires) -- Innocan Pharma ( INNPF ) said Tuesday it engaged the Past-President of the Eastern Pain Association, Dr. William K. Schmidt, to support its LPT-CBD submission process to the Food and Drug Administration for chronic pain.

Dr. Schmidt brings over 25 years of pharmaceutical industry clinical trial experience, specializing in analgesic and narcotic antagonist drug development. He has held key positions at several pharmaceutical companies, including CrystalGenomics, Limerick BioPharma, Renovis, Inc., Adolor Corporation, and DuPont Merck, the company said.

"We are thrilled to have Dr. Schmidt as part of our LPT-CBD submission expert team," Innocan chief executiive Iris Bincovich said in a statement. "His extensive expertise in pain-related clinical development and regulatory affairs will strongly contribute to our LPT-CBD submission process with the FDA. His expertise significantly strengthens our team as we work towards FDA approval."

The company's shares closed down $0.02 to $0.225 on the Canadian Securities Exchange.